Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study

This study aimed to prospectively evaluate, on a long-term basis, corneal side effects secondary to compassionate administration of epidermal growth factor receptor (EGFR) inhibitor depatuxizumab mafodotin (ABT-414) in patients affected by EGFR-amplified recurrent glioblastoma. Fifteen patients with...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Oncol
Glavni autori: Parrozzani, Raffaele, Lombardi, Giuseppe, Midena, Edoardo, Londei, Davide, Padovan, Marta, Marchione, Giulia, Caccese, Mario, Midena, Giulia, Zagonel, Vittorina, Frizziero, Luisa
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2020
Teme:
Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7591744/
https://ncbi.nlm.nih.gov/pubmed/33154952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.593461
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items